Annotation Detail
Information
- Associated Genes
- FGFR1
- Associated Variants
-
FGFR1 EXPRESSION
FGFR1 EXPRESSION - Associated Disease
- lung cancer
- Source Database
- CIViC Evidence
- Description
- Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/681
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1885
- Variant URL
- https://civic.genome.wustl.edu/links/variants/268
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Cancer
- Evidence Direction
- Supports
- Drug
- Ponatinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24771645
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ponatinib | Sensitivity | true |